Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SRZNW
Upturn stock ratingUpturn stock rating

Surrozen Inc. Warrant (SRZNW)

Upturn stock ratingUpturn stock rating
$0.01
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: SRZNW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -50%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.57
52 Weeks Range 0.01 - 0.09
Updated Date 05/20/2025
52 Weeks Range 0.01 - 0.09
Updated Date 05/20/2025
Dividends yield (FY) -
Basic EPS (TTM) -5.7

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -971.62%

Management Effectiveness

Return on Assets (TTM) -21.41%
Return on Equity (TTM) -456.32%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 5400593
Shares Outstanding -
Shares Floating 5400593
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Surrozen Inc. Warrant

stock logo

Company Overview

overview logo History and Background

Surrozen, Inc. was a preclinical biopharmaceutical company focused on discovering and developing novel regenerative medicines with a focus on modulating the Wnt signaling pathway. The warrant (SRZN.WS) existed due to the company's public debut via a merger, and represents the right to purchase shares of Surrozen stock.

business area logo Core Business Areas

  • Wnt Signaling Drug Development: Focused on developing therapies that stimulate the body's own repair mechanisms using Wnt signaling.

leadership logo Leadership and Structure

Information about the leadership and organizational structure of Surrozen Inc. is limited since it ceased operations. It was previously a publicly traded company with a standard leadership team structure, prior to winding down.

Top Products and Market Share

overview logo Key Offerings

  • SZN-1326: A potential treatment for severe alcoholic hepatitis and other liver diseases. Preclinical stage. Competitors include companies developing therapies for liver diseases, such as Gilead Sciences (GILD) and Intercept Pharmaceuticals (ICPT), although their mechanisms differ from Surrozen's Wnt activation approach. It did not get to market.
  • SZN-043: A potential treatment for inflammatory bowel disease (IBD). Preclinical stage. Competitors include companies developing IBD therapies, such as AbbVie (ABBV) and Takeda (TAK), although their mechanisms differ from Surrozen's Wnt activation approach. It did not get to market.

Market Dynamics

industry overview logo Industry Overview

The regenerative medicine industry is characterized by significant unmet need and high potential. The industry is highly competitive with both established pharmaceutical companies and smaller biotech firms pursuing novel therapeutic approaches.

Positioning

Surrozen aimed to position itself as a leader in Wnt signaling-based regenerative medicine. Given the company ceased operations, its positioning is now moot.

Total Addressable Market (TAM)

The TAM for regenerative medicine targeting liver diseases and IBD is substantial, estimated to be in the billions of dollars. Surrozen's Wnt-based approach sought to capture a portion of this market, but that will not be realized.

Upturn SWOT Analysis

Strengths

  • Novel Wnt signaling technology platform
  • Potential for regenerative medicine breakthroughs

Weaknesses

  • Preclinical stage programs
  • High cash burn rate
  • Dependence on successful clinical trials
  • Company Ceased operations

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Positive clinical trial results

Threats

  • Clinical trial failures
  • Competition from other regenerative medicine approaches
  • Regulatory hurdles
  • Funding constraints

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

Surrozen faced competition from large and small pharmaceutical companies developing therapies for liver diseases and IBD. Its novel Wnt signaling approach offered a potential differentiator, but the company failed to overcome its challenges.

Growth Trajectory and Initiatives

Historical Growth: Surrozen Inc. did not achieve significant revenue or commercial success before ceasing operations.

Future Projections: No future projections are available since the company has ceased operations.

Recent Initiatives: Prior to its shutdown, Surrozen Inc. was focused on advancing its preclinical programs.

Summary

Surrozen Inc. was a preclinical biopharmaceutical company focused on regenerative medicine that ultimately ceased operations. While it possessed a novel Wnt signaling platform, it faced challenges in securing funding and advancing its programs through clinical trials. As a result, it was unable to capitalize on its potential and deliver value to shareholders. The warrants (SRZN.WS) became worthless, as the company was dissolved.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (prior to delisting)
  • Financial News Outlets (prior to cessation of operations)

Disclaimers:

This analysis is based on publicly available information prior to the company's cessation of operations. The information provided is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Surrozen Inc. Warrant

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2021-08-12
CEO, President & Director Mr. Craig C. Parker M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 40
Full time employees 40

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.